These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
217 related items for PubMed ID: 10697615
1. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study. Schutter EM, Mijatovic V, Kok A, Van Kamp GJ, Verstraeten R, Verheijen RH. Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615 [Abstract] [Full Text] [Related]
2. Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers. Plebani M, Navaglia F, Basso D, De Paoli M, Nicoletto MO, Maraglino E, Torre GC. Anticancer Res; 1996; 16(6B):3833-8. PubMed ID: 9042266 [Abstract] [Full Text] [Related]
3. Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies. Walker R, Crebbin V, Stern J, Scudder S, Schwartz P. Anticancer Res; 1994; 14(5A):1703-9. PubMed ID: 7847804 [Abstract] [Full Text] [Related]
4. UGP--a tumor marker of gynecologic and breast malignancies? Specificity and sensitivity in pretherapeutic patients and the influence of hormonal substitution on the expression of UGP. Schwarz-Roeger U, Petzoldt B, Waldschmidt R, Walker RP, Bauknecht T, Kiechle M. Anticancer Res; 1997; 17(4B):3041-5. PubMed ID: 9329597 [Abstract] [Full Text] [Related]
5. Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report. Cole LA, Tanaka A, Kim GS, Park SY, Koh MW, Schwartz PE, Chambers JT, Nam JH. Gynecol Oncol; 1996 Feb; 60(2):264-70. PubMed ID: 8631549 [Abstract] [Full Text] [Related]
6. UGP in urogenital disorders: Egyptian experience. el-Ahmady O, Halim AB, Gad M, Walker R. Anticancer Res; 1996 Feb; 16(4B):2301-8. PubMed ID: 8694560 [Abstract] [Full Text] [Related]
7. [Preliminary experience with a new tumor marker in obstetrics and gynecology: UGP (Urinary Gonadotropin Protein)]. Radici E, Persiani P, Stroppa S, Lombardi PL, Torre GC. Minerva Ginecol; 1996 Feb; 48(1-2):5-9. PubMed ID: 8750482 [Abstract] [Full Text] [Related]
8. Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers. Cole LA, Wang YX, Elliott M, Latif M, Chambers JT, Chambers SK, Schwartz PE. Cancer Res; 1988 Mar 01; 48(5):1356-60. PubMed ID: 3342414 [Abstract] [Full Text] [Related]
9. Clinical applications of urinary gonadotropin peptides (UGP) in gynecologic oncology. Schwartz PE, Cracchiolo BM, Cole LA. Anticancer Res; 1996 Mar 01; 16(4B):2135-9. PubMed ID: 8694533 [Abstract] [Full Text] [Related]
10. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy]. Dong L, Chang XH, Ye X, Zhu LR, Zhao Y, Tian L, Cheng HY, Li XP, Zhang H, Liao QP, Fu TY, Cheng YX, Cui H. Zhonghua Fu Chan Ke Za Zhi; 2008 Dec 01; 43(12):931-6. PubMed ID: 19134334 [Abstract] [Full Text] [Related]
11. Following metastatic placental site trophoblastic tumor with urine beta-core fragment. Rinne K, Shahabi S, Cole L. Gynecol Oncol; 1999 Aug 01; 74(2):302-3. PubMed ID: 10419751 [Abstract] [Full Text] [Related]
12. Urinary gonadotropin peptide in patients with cancer of digestive organs. Motoo Y, Watanabe H, Yamaguchi Y, Mouri I, Fujii T, Yamakawa O, Satomura Y, Okai T, Sawabu N. Anticancer Res; 1996 Aug 01; 16(4A):2041-8. PubMed ID: 8712740 [Abstract] [Full Text] [Related]
13. Urinary cyclic GMP after treatment of gynecological cancer. A prognostic marker of clinical outcome. Orbo A, Hanevik M, Jaeger R, Van Heusden S, Sager G. Anticancer Res; 2007 Aug 01; 27(4C):2591-6. PubMed ID: 17695420 [Abstract] [Full Text] [Related]
14. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Allard J, Moore RG, Lu KH, Bast RC. Gynecol Oncol; 2007 Sep 01; 106(3):490-7. PubMed ID: 17532030 [Abstract] [Full Text] [Related]
15. [Development of highly sensitive enzyme immunoassay to measure urinary beta-core fragment in patients with gynecological cancer]. Nishimura R, Kobayashi K, Katsuno M, Kobayashi T. Nihon Sanka Fujinka Gakkai Zasshi; 1990 Feb 01; 42(2):143-8. PubMed ID: 1690253 [Abstract] [Full Text] [Related]
16. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer. Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB. Acta Obstet Gynecol Scand; 2008 Feb 01; 87(11):1136-42. PubMed ID: 18951217 [Abstract] [Full Text] [Related]
17. [Use of biochemical markers to predict the outcome of pregnancies conceived by in vitro fertilization]. Hauzman E, Murber A, Fancsovits P, Papp Z, Urbancsek J. Orv Hetil; 2006 Jul 30; 147(30):1409-20. PubMed ID: 16977779 [Abstract] [Full Text] [Related]
18. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study. Sehouli J, Akdogan Z, Heinze T, Könsgen D, Stengel D, Mustea A, Lichtenegger W. Anticancer Res; 2003 Jul 30; 23(2A):1115-8. PubMed ID: 12820357 [Abstract] [Full Text] [Related]
19. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Petri AL, Simonsen AH, Yip TT, Hogdall E, Fung ET, Lundvall L, Hogdall C. Acta Obstet Gynecol Scand; 2009 Jul 30; 88(1):18-26. PubMed ID: 19023702 [Abstract] [Full Text] [Related]
20. Serum C-reactive protein in the differential diagnosis of ovarian masses. Hefler-Frischmuth K, Hefler LA, Heinze G, Paseka V, Grimm C, Tempfer CB. Eur J Obstet Gynecol Reprod Biol; 2009 Nov 30; 147(1):65-8. PubMed ID: 19619929 [Abstract] [Full Text] [Related] Page: [Next] [New Search]